- Under the NCIB, the company will purchase up to 1,925,210 subordinate voting shares between January 18, 2023, and January 17, 2024
- All shares acquired under the bid will be returned to treasury and cancelled
- The company repurchased 1,999,800 subordinate voting shares under its previous NCIB that ended on December 31, 2022
- FSD Pharma Inc is a biopharmaceutical company
- FSD Pharma Inc. (HUGE) is up 7.44 per cent on the day, trading at C$1.30 per share at 2 pm ET
FSD Pharma (HUGE) has announced a normal course issuer bid (NCIB).
Under the NCIB, the company will purchase up to 1,925,210 subordinate voting shares, approximately 5 per cent of the company’s issued and outstanding subordinate voting shares.
The bid will commence on January 18, 2023, and end on January 17, 2024. All shares acquired under the bid will be returned to treasury and cancelled.
The company repurchased 1,999,800 subordinate voting shares at an average price of approximately $1.20 per share under a normal course issuer bid that ended on December 30, 2022.
FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders.
FSD Pharma Inc. (HUGE) is up 7.44 per cent on the day, trading at C$1.30 per share at 2 pm ET.
